Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 6/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990262 | 0.95 | POLB (0.61) | POLBLTA4HHTR6 | |
| SCHEMBL1990261 | 0.95 | POLB (0.61) | POLBLTA4HHTR6 | |
| SCHEMBL29538076 | 0.95 | POLB (0.61) | POLBLTA4HHTR6 | |
| SCHEMBL24881530 | 0.82 | POLB (0.69) | POLBHRH3LTA4H | |
| SCHEMBL18577477 | 0.82 | POLB (0.69) | POLBHRH3LTA4H | |
| SCHEMBL21788551 | 0.82 | POLB (0.69) | POLBHRH3LTA4HHTR6 | |
| SCHEMBL18577474 | 0.82 | POLB (0.69) | POLBHRH3LTA4H | |
| SCHEMBL27520674 | 0.82 | POLB (0.69) | POLBHRH3LTA4HHTR6 | |
| SCHEMBL27448154 | 0.82 | POLB (0.48) | POLBLTA4H | |
| SCHEMBL2707343 | 0.81 | POLB (1.00) | POLBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1617743-A | New pharmaceutical combinations for nos inhibitors | PFIZER PROD INC (US) | 2005-05-18 | — | — | CN | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | disclosed |
| CN-1117077-C | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER (US) | 2003-08-06 | — | — | CN | disclosed |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| CN-1323211-A | New pharmaceutical use of NOS inhibitors | PFIZER PROD INC (US) | 2001-11-21 | — | — | CN | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6235750-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| CN-1239952-A | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER (US) | 1999-12-29 | — | — | CN | disclosed |
| EP-0946512-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024766-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | POLB 1428/4885HRH3 1527/4885LTA4H 1453/4885 |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | POLB 2410/4885HRH3 1390/4885LTA4H 2931/4885 |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | POLB 2410/4885HRH3 1390/4885LTA4H 2931/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | POLB 2492/4885HRH3 1487/4885LTA4H 2624/4885 |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | POLB 2410/4885HRH3 1390/4885LTA4H 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.